Comparison variables | Overall survival | Progression-free survival | ||||
---|---|---|---|---|---|---|
Number of studies, Heterogeneity (I2 statistics; %) | HR 95 % CI, P value | Interaction, P value | Number of studies, Heterogeneity (I2 statistics; %) | HR 95 % CI, P value | Interaction, P value | |
Total | 8 (75.8) | 1.75 (1.19–2.58), 0.004 | NA | 5 (71.5) | 1.55 (0.96–2.51), 0.074 | NA |
Origin country | ||||||
Europe | 5 (73.1) | 1.52 (1.04–2.21), 0.029 | 0.014 | 4 (74.1) | 1.76 (0.98–3.14), 0.057 | 0.142 |
Asian | 2 (81.8) | 1.92 (0.43–8.62), 0.393 | 1 (NA) | 1.55 (0.96–2.51), 0.973 | ||
USA | 1 (NA) | 13.42 (2.56–70.34), 0.002 | ||||
Sample size | ||||||
>50 | 5 (71.6) | 1.41 (1.00–1.98), 0.051 | 0.005 | 3 (82.6) | 1.39 (0.77–2.50), 0.277 | 0.322 |
≤50 | 3 (71.2) | 3.61 (0.99–13.17), 0.052 | 2 (36.5) | 2.14 (0.85–5.35), 0.105 | ||
Follow up period | ||||||
1,>media 12months | 2 (68.7) | 4.96 (1.08–22.78), 0.040 | 0.001 | 1 (NA) | 2.40 (1.60–3.40), 0.000 | 0.008 |
2,≤media 12months | 3 (68.8) | 1.64 (0.74–3.67), 0.225 | 3 (55.4) | 1.49 (0.76–2.94), 0.246 | ||
3,No Referreed | 3 (66.8) | 1.35 (0.77–2.38), 0.300 | 1 (NA) | 1.01 (0.57–1.79), 0.973 | ||
Median/mean age y | ||||||
Referred | 3 (83.4) | 3.36 (0.72–15.61), 0.123 | 0.154 | 1 (NA) | 1.01 (0.57–1.80), 0.973 | 0.142 |
No Referred | 5 (75.8) | 1.52 (1.04–2.21), 0.029 | 4 (74.7) | 1.76 (0.98–3.14), 0.057 | ||
Test method | ||||||
IHC | 5 (82.1) | 2.11 (1.10–4.04), 0.025 | 0.671 | 2 (83.6) | 1.60 (0.69–3.73), 0.275 | 0.063 |
Others | 3 (68.8) | 1.64 (0.74–3.67), 0.225 | 3 (55.4) | 1.49 (0.76–2.51), 0.246 | ||
Cut‑off level | ||||||
1:median | 5 (74.1) | 1.55 (1.00–2.42), 0.050 | 0.021 | 3 (55.4) | 1.49 (0.76–2.94), 0.246 | 0.063 |
2:others | 3 (75.6) | 2.10 (0.88–5.00), 0.093 | 2 (83.6) | 1.60 (0.69–3.73), 0.275 | ||
WHO grade | ||||||
IV | 2 (0.0) | 1.09 (0.83–1.44), 0.518 | 0.000 | 2 (0.00) | 1.04 (0.77–1.41), 0.808 | 0.000 |
II–III | 4 (57.2) | 3.11 (1.45–6.67), 0.004 | 3 (0.00) | 2.34 (1.68–3.27), 0.000 |